Clinical Outcomes With Pembrolizumab-Based Therapies in Recurrent/Refractory NSCLC After Chemoradiation and Consolidative Durvalumab
Lukas Delasos, Wei Wei, Khaled A. Hassan, Nathan A. Pennell, Pradnya D. Patil, James Stevenson
Topics & Concepts
MedicinePembrolizumabDurvalumabInternal medicineOncologyRefractory (planetary science)Lung cancerCohortPopulationImmunotherapyCancerAstrobiologyPhysicsEnvironmental healthCancer Immunotherapy and BiomarkersLymphoma Diagnosis and TreatmentLung Cancer Diagnosis and Treatment